India's cardiovascular and diabetes burden is no longer an emerging healthcare challenge; it has become one of the defining public health realities of the decade. With changing dietary habits, sedentary lifestyles, increasing stress levels, and an ageing yet economically active population, the country is witnessing an unprecedented rise in metabolic disorders.
What makes the situation particularly complex is that these conditions are no longer confined to metropolitan centres. Smaller cities and rural districts are experiencing comparable, and in many cases faster, growth in diabetes and cardiovascular disease prevalence, exposing significant gaps in early diagnosis, patient education, and long-term disease management.
While pharmaceutical innovation continues to introduce newer therapies, the industry's challenge has shifted beyond developing effective molecules. New generation of healthcare companies are beginning to rethink the role of pharmaceutical organisations.
Rather than positioning medicines as standalone products, they are integrating digital technology, clinical intelligence, behavioural interventions, and physician enablement into a unified care ecosystem. This evolution reflects a broader shift in Indian healthcare, from product-centric treatment to outcome-centric disease management.
Kollectcare represents this new direction. Built as a pharmaceutical company dedicated exclusively to cardiovascular and diabetes care, the organisation develops therapies tailored to Indian patients while integrating artificial intelligence, patient education, physician engagement, and real-world clinical evidence to strengthen treatment outcomes.
Rather than positioning digital technologies as the business itself, Kollectcare uses them to extend the value of its pharmaceutical portfolio and improve long-term disease management. Instead of adapting global treatment frameworks to Indian conditions, the company has deliberately designed its approach around Indian metabolic profiles, dietary patterns, and healthcare realities.
From Rural Healthcare Data to a Purpose- Built Pharma Platform
Kollectcare's origins lie not in conventional pharmaceutical manufacturing but in years of healthcare delivery across underserved India. Its foundation emerged from the experience of Tattvan E-Clinics, which operated more than 600 clinics across 218 Tier III and beyond districts, treating close to one million patients over several years.
Within less than a year of commercial launch, Kollectcare has expanded its presence across nearly 70 districts in North India, reflecting rapid physician acceptance and growing demand for its India-focused cardio-diabetes portfolio.
This extensive clinical footprint generated insights that traditional pharmaceutical market research rarely captures. The data revealed an accelerating burden of cardiovascular disease and diabetes among younger populations outside metropolitan India, alongside significant deficiencies in patient education and disease awareness.
Physicians, despite recognising these challenges, often lacked sufficient consultation time to provide comprehensive counselling, while many patients continued on older therapies simply because they were unaware of newer treatment options.
Rather than treating these findings as isolated operational issues, Kollectcare used them as the blueprint for an entirely new pharmaceutical model. The company was established with the objective of developing therapies specifically aligned with Indian patient characteristics while embedding education, digital engagement, and physician support into every stage of treatment.
This philosophy distinguishes Kollectcare from companies whose primary focus remains product distribution. Here, pharmaceutical development begins with understanding patient behaviour and clinical realities before progressing towards formulation and therapy design.
Building a Pharmaceutical Portfolio for Indian Patients
At the heart of Kollectcare's strategy is its pharmaceutical portfolio, developed specifically for Indian cardiovascular and diabetes patients. Rather than viewing diabetes as a single disease, the company recognises the diverse metabolic characteristics commonly seen among Indian populations, including central obesity, fatty liver disease, insulin resistance, pronounced post-meal glucose spikes, and earlier cardiovascular complications.
This phenotype-based understanding guides the development of therapies designed for different clinical presentations instead of relying on a one-size-fits-all treatment approach.
This understanding has shaped a therapeutic portfolio addressing different clinical presentations rather than relying on a single treatment pathway.
Products such as KC MeSempa have been positioned for cardiovascular risk reduction among younger diabetic patients, while KC SPM targets patients presenting with insulin resistance and fatty liver. Complementary therapies including KC GPM have been developed for cost-sensitive individuals with poorly controlled diabetes, whereas KC GliTri addresses post-prandial glucose control, a particularly relevant concern given India's carbohydrate-rich dietary habits.
The company has also expanded beyond prescription medicines through metabolic support products such as KC Cal D3 and is advancing a plant-based GLP-1 nutraceutical designed to improve accessibility for patients who remain unable to afford high-cost injectable therapies.
Underlying this portfolio is a broader strategy: tailoring pharmaceutical interventions to Indian disease patterns instead of simply replicating treatment models developed for Western populations.
Kollectcare is among the first branded-generic pharmaceutical companies in India's cardio-diabetes segment to embed prospective real-world evidence generation as a continuous product-lifecycle activityKaustubh Kiran, Chief Commercial Officer & Member of the Board, Atul Kumar Mishra, President & Board Member and Akshat Bhatnagar, Chief Corporate Officer
Extending Pharmaceutical Care Through Digital Innovation
Instead of replacing traditional pharmaceutical engagement, Kollectcare uses artificial intelligence to strengthen physician support, improve patient education, and enhance long-term therapy adherence.
Digital platforms therefore function as extensions of its pharmaceutical care model, helping clinicians deliver more personalised care beyond the consultation room.
Its flagship platform, CareEasy, generates personalised meal plans within seconds based on patient-specific variables including blood sugar levels, body weight, dietary preferences, and regional food habits. These recommendations are delivered directly through WhatsApp, enabling physicians to extend dietary counselling beyond the clinic without increasing consultation time.
Recognising that patient education remains one of chronic disease management's weakest links, the company has also developed an AI-powered content platform allowing healthcare professionals to create customised educational videos in their own voice and language. Instead of relying on generic awareness material, physicians can now provide personalised educational resources that patients can revisit after leaving the clinic.
“Kollectcare has further strengthened public engagement through DocTalk, a digital educational initiative featuring leading clinicians discussing cardiovascular disease, diabetes management, and preventive healthcare across YouTube and Instagram. By creating credible, doctor-led educational content at scale, the initiative seeks to improve health literacy while reinforcing physician-patient communication outside conventional consultations”, highlights Ayush Atul Mishra.
Internally, artificial intelligence also supports adherence prediction, patient dropout modelling, and ongoing refinement of clinical protocols using continuously generated real-world data, creating a feedback loop between research, clinical practice, and patient outcomes.
Advancing Indian Research through Real- World Evidence
Beyond commercial expansion, Kollectcare has placed significant emphasis on generating scientific evidence relevant to Indian patients. Its research strategy begins with identifying unmet clinical needs before evaluating therapeutic combinations, rather than building research exclusively around available molecules.
Artificial intelligence assists this process by modelling expected treatment responses across different Indian patient subgroups before clinical studies commence, helping prioritise promising development pathways.
Among its major research initiatives is a prospective 500-patient real-world evidence study evaluating KC MeSempa. Unlike conventional clinical trials conducted under tightly controlled environments, real-world evidence examines how therapies perform during routine medical practice, providing clinicians with insights into effectiveness, adherence, and long-term outcomes within actual patient populations.
Kollectcare is among the first branded-generic pharmaceutical companies in India's cardio-diabetes segment to embed prospective real-world evidence generation as a continuous product-lifecycle activity. Rather than treating clinical evidence as a one-time exercise, the company continuously evaluates therapeutic performance in routine clinical practice, enabling ongoing refinement of treatment strategies and generating India-specific evidence for physicians.
Simultaneously, Kollectcare continues developing new formulations targeting multiple Indian diabetes phenotypes, including therapies addressing cardiovascular protection, insulin resistance, post-meal glucose control, fatty liver disease, and simplified once-daily treatment regimens. Several of these programmes are progressing towards regulatory submission.
This sustained investment in Indian clinical evidence reflects the company's broader objective of ensuring that treatment decisions are increasingly informed by domestic patient data rather than depending solely on international studies.
Scaling a New Model of Cardio-Diabetes Care
Looking ahead, Kollectcare aims to strengthen its position as a pharmaceutical company dedicated to India's growing cardio-diabetes burden by expanding its portfolio of India-focused therapies while continuing to invest in physician enablement, patient education, and real-world clinical research.
As India's burden of chronic metabolic disease continues to rise, pharmaceutical success will increasingly depend not only on therapeutic innovation but also on improving patient understanding, physician efficiency, and long-term treatment adherence.
By combining pharmaceutical science with artificial intelligence, digital health infrastructure, and data-driven clinical research, Kollectcare is positioning itself at the intersection of these evolving priorities, contributing to a healthcare model where medicines become one component of a much broader system designed to improve patient outcomes.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")